Theravance Biopharma (NASDAQ:TBPH) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Theravance Biopharma (NASDAQ:TBPH) from a buy rating to a strong-buy rating in a report released on Tuesday.

Other analysts have also issued research reports about the company. B. Riley Financial lifted their price objective on Theravance Biopharma from $14.00 to $17.00 and gave the stock a “neutral” rating in a report on Tuesday, April 7th. TD Cowen lifted their price objective on Theravance Biopharma from $13.00 to $15.00 and gave the stock a “hold” rating in a report on Monday, March 23rd. Weiss Ratings lowered Theravance Biopharma from a “buy (b-)” rating to a “hold (c+)” rating in a report on Friday, April 10th. HC Wainwright lifted their price objective on Theravance Biopharma from $20.00 to $27.00 and gave the stock a “buy” rating in a report on Monday, March 2nd. Finally, Oppenheimer lowered Theravance Biopharma from an “outperform” rating to a “market perform” rating in a report on Thursday, March 5th. Two equities research analysts have rated the stock with a Strong Buy rating, two have assigned a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat.com, Theravance Biopharma has an average rating of “Moderate Buy” and an average price target of $21.83.

Theravance Biopharma Price Performance

Shares of TBPH opened at $16.78 on Tuesday. Theravance Biopharma has a one year low of $8.33 and a one year high of $21.03. The firm has a market capitalization of $864.05 million, a P/E ratio of 8.27 and a beta of 0.17. The business has a fifty day moving average of $16.49 and a 200 day moving average of $17.11.

Insiders Place Their Bets

In related news, SVP Rhonda Farnum sold 31,067 shares of Theravance Biopharma stock in a transaction on Monday, March 16th. The stock was sold at an average price of $13.96, for a total transaction of $433,695.32. Following the transaction, the senior vice president directly owned 232,699 shares in the company, valued at approximately $3,248,478.04. The trade was a 11.78% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 6.90% of the company’s stock.

Hedge Funds Weigh In On Theravance Biopharma

Several institutional investors and hedge funds have recently bought and sold shares of TBPH. AQR Capital Management LLC purchased a new position in Theravance Biopharma during the first quarter valued at $101,000. Jane Street Group LLC lifted its position in Theravance Biopharma by 169.2% during the first quarter. Jane Street Group LLC now owns 140,884 shares of the biopharmaceutical company’s stock valued at $1,258,000 after purchasing an additional 88,540 shares in the last quarter. Creative Planning purchased a new position in shares of Theravance Biopharma in the second quarter valued at about $139,000. American Century Companies Inc. lifted its position in shares of Theravance Biopharma by 6.8% in the second quarter. American Century Companies Inc. now owns 91,501 shares of the biopharmaceutical company’s stock valued at $1,009,000 after acquiring an additional 5,794 shares in the last quarter. Finally, Invesco Ltd. lifted its position in shares of Theravance Biopharma by 12.4% in the second quarter. Invesco Ltd. now owns 25,324 shares of the biopharmaceutical company’s stock valued at $279,000 after acquiring an additional 2,789 shares in the last quarter. 99.10% of the stock is currently owned by hedge funds and other institutional investors.

Theravance Biopharma Company Profile

Theravance Biopharma is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, primarily in the areas of respiratory disease, inflammatory and immunology, and rare disorders. The company develops small-molecule therapies designed to address unmet medical needs by targeting specific molecular pathways. Its lead marketed product, YUPELRI® (revefenacin) inhalation solution, is the first and only once-daily, long-acting muscarinic antagonist (LAMA) approved by the U.S.